Myogem Health Company S.L. is a company located in Mollet del Valles, Barcelona, Spain.
The company is a spin-off of Inkemia IUCT Group, focused on the research, development, innovation, and commercialization of new nutritional products aimed at improving the quality of life of people affected by certain rare diseases or conditions with high social incidence.
A rare disease is one that affects a small absolute number of people or a small proportion of the population. In Europe, a disease is considered “rare” if it affects fewer than 1 in 2,000 people. In the United States, it is defined as a disorder or disease affecting fewer than 200,000 people.
Myogem Health Company’s mission is to offer patients affected by these diseases the possibility of having a better quality of life through a range of dietary supplements designed to improve their nutritional status.
Currently, Myogem Health Company focuses its research on finding new nutritional solutions aimed at neuromuscular-origin diseases, such as Myotonic Dystrophy type 1 or Steinert’s Disease.
Our Goal
Traditionally, medications have been considered the only option to improve quality of life. However, many factors influence quality of life, which can be modulated by enhancing vitality, general health perception, physical, emotional, and social condition, and an individual’s mental health.
A current approach to improving quality of life consists of the nutritional management of the pathological condition that is limiting it.
Myogem Health Company aims to be a leading company in the research and development of nutritional products based on food ingredients that contribute to improving the quality of life and nutritional status of people affected by certain rare diseases, such as Myotonic Dystrophy type 1, and other related conditions.
